BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) (the “Company” or “RegeneRx”) announced today that it received a “Notice of Allowance” in Europe for its patent application: Inhibition or Reversal of Skin Aging by Actin-Sequestering Peptides. The patent covers methods, uses and compositions containing thymosin beta 4 (Tß4), and variations and components thereof, to improve the appearance of skin, including skin that is aged, dry, lined and wrinkled.
